Altrinsic Global Advisors LLC Ionis Pharmaceuticals Inc Transaction History

Altrinsic Global Advisors LLC

$2.13 Billion
Q1 2024

A detailed history of Altrinsic Global Advisors LLC transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Altrinsic Global Advisors LLC holds 194,864 shares of IONS stock, worth $9.29 Million. This represents 0.4% of its overall portfolio holdings.

Number of Shares

194,864

Previous 209,152 6.83%

Holding current value

$9.29 Million

Previous $10.6 Million 20.16%

% of portfolio

0.4%

Previous 0.46%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$42.03 - $53.55 $600,524 - $765,122	-14,288 Reduced 6.83%	194,864 $8.45 Million
Q4 2023 Feb 14, 2024	SELL	$43.39 - $51.63 $3.6 Million - $4.29 Million	-83,032 Reduced 28.42%	209,152 $10.6 Million
Q3 2023 Nov 14, 2023	SELL	$38.5 - $47.13 $608,531 - $744,936	-15,806 Reduced 5.13%	292,184 $13.3 Million
Q2 2023 Aug 14, 2023	SELL	$34.73 - $43.33 $496,326 - $619,229	-14,291 Reduced 4.43%	307,990 $12.6 Million
Q1 2023 May 15, 2023	BUY	$33.58 - $41.2 $104,333 - $128,008	3,107 Added 0.97%	322,281 $11.5 Million

Q4 2022 Feb 14, 2023	BUY	$37.12 - $46.52 $5.86 Million - $7.35 Million	157,928 Added 97.94%	319,174 $12.1 Million
Q3 2022 Nov 14, 2022	SELL	$36.54 - $48.66 $921,100 - $1.23 Million	-25,208 Reduced 13.52%	161,246 $7.13 Million
Q2 2022 Aug 15, 2022	SELL	$31.71 - $43.0 $688,233 - $933,272	-21,704 Reduced 10.43%	186,454 $6.9 Million
Q1 2022 May 16, 2022	SELL	$29.88 - $37.04 $5.71 Million - $7.08 Million	-191,234 Reduced 47.88%	208,158 $7.71 Million
Q4 2021 Feb 14, 2022	SELL	$25.61 - $35.1 $1.17 Million - $1.6 Million	-45,495 Reduced 10.23%	399,392 $12.2 Million
Q3 2021 Nov 15, 2021	SELL	$33.54 - $40.55 $380,310 - $459,796	-11,339 Reduced 2.49%	444,887 $14.9 Million
Q2 2021 Aug 13, 2021	BUY	$34.54 - $47.25 $524,040 - $716,877	15,172 Added 3.44%	456,226 $18.2 Million
Q1 2021 May 14, 2021	BUY	$42.51 - $63.78 $4.18 Million - $6.27 Million	98,280 Added 28.67%	441,054 $19.8 Million
Q4 2020 Feb 16, 2021	SELL	$45.3 - $60.27 $53,363 - $70,998	-1,178 Reduced 0.34%	342,774 $19.4 Million
Q3 2020 Nov 16, 2020	BUY	$47.45 - $62.95 $144,817 - $192,123	3,052 Added 0.9%	343,952 $16.3 Million
Q2 2020 Aug 14, 2020	SELL	$46.85 - $61.05 $371,707 - $484,370	-7,934 Reduced 2.27%	340,900 $20.1 Million
Q1 2020 May 14, 2020	BUY	$41.6 - $63.4 $3.21 Million - $4.9 Million	77,266 Added 28.45%	348,834 $16.5 Million
Q4 2019 Feb 14, 2020	SELL	$53.85 - $65.27 $949,375 - $1.15 Million	-17,630 Reduced 6.1%	271,568 $16.4 Million
Q3 2019 Nov 14, 2019	BUY	$59.06 - $72.15 $6.52 Million - $7.96 Million	110,384 Added 61.73%	289,198 $17.3 Million
Q2 2019 Aug 14, 2019	SELL	$62.09 - $86.14 $3.65 Million - $5.07 Million	-58,831 Reduced 24.76%	178,814 $11.5 Million
Q1 2019 May 14, 2019	SELL	$52.92 - $81.17 $15.4 Million - $23.6 Million	-290,614 Reduced 55.01%	237,645 $19.3 Million
Q4 2018 Feb 14, 2019	BUY	$43.37 - $59.54 $175,258 - $240,601	4,041 Added 0.77%	528,259 $28.6 Million
Q3 2018 Nov 14, 2018	BUY	$42.88 - $53.7 $115,904 - $145,151	2,703 Added 0.52%	524,218 $27 Million
Q2 2018 Aug 13, 2018	BUY	$40.53 - $50.7 $3.22 Million - $4.03 Million	79,390 Added 17.96%	521,515 $21.7 Million
Q1 2018 May 14, 2018	SELL	$44.08 - $55.05 $988,934 - $1.24 Million	-22,435 Reduced 4.83%	442,125 $19.5 Million
Q4 2017 Feb 13, 2018	SELL	$50.3 - $64.39 $7.04 Million - $9.01 Million	-139,895 Reduced 23.14%	464,560 $23.4 Million
Q3 2017 Nov 14, 2017	BUY	$45.56 - $59.57 $27.5 Million - $36 Million	604,455	604,455 $30.6 Million

Others Institutions Holding IONS

# of Institutions

396

Shares Held

122M

Call Options Held

854K

Put Options Held

464K

View Full List

About IONIS PHARMACEUTICALS INC

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $6.76B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

More about IONS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Altrinsic Global Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Altrinsic Global Advisors LLC with notifications on news.

Account

Altrinsic Global Advisors LLC Ionis Pharmaceuticals Inc Transaction History